BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Turku A, Borrel A, Leino TO, Karhu L, Kukkonen JP, Xhaard H. Pharmacophore Model To Discover OX 1 and OX 2 Orexin Receptor Ligands. J Med Chem 2016;59:8263-75. [DOI: 10.1021/acs.jmedchem.6b00333] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Tsuneki H, Wada T, Sasaoka T. Chronopathophysiological implications of orexin in sleep disturbances and lifestyle-related disorders. Pharmacology & Therapeutics 2018;186:25-44. [DOI: 10.1016/j.pharmthera.2017.12.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
2 Boss C, Roch C. Orexin research: patent news from 2016. Expert Opinion on Therapeutic Patents 2017;27:1123-33. [DOI: 10.1080/13543776.2017.1344221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
3 Janockova J, Dolezal R, Nepovimova E, Kobrlova T, Benkova M, Kuca K, Konecny J, Mezeiova E, Melikova M, Hepnarova V, Ring A, Soukup O, Korabecny J. Investigation of New Orexin 2 Receptor Modulators Using In Silico and In Vitro Methods. Molecules 2018;23:E2926. [PMID: 30423961 DOI: 10.3390/molecules23112926] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Rinne M, Tanoli ZU, Khan A, Xhaard H. Cartography of rhodopsin-like G protein-coupled receptors across vertebrate genomes. Sci Rep 2019;9:7058. [PMID: 31064998 DOI: 10.1038/s41598-018-33120-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
5 Kukkonen JP. Allosteric interactions via the orthosteric ligand binding sites in a constitutive G-protein-coupled receptor homodimer. Pharmacol Res 2021;166:105116. [PMID: 32783977 DOI: 10.1016/j.phrs.2020.105116] [Reference Citation Analysis]
6 Karhu L, Weisell J, Turunen PM, Leino TO, Pätsi H, Xhaard H, Kukkonen JP, Wallén EAA. Stapled truncated orexin peptides as orexin receptor agonists. Peptides 2018;102:54-60. [PMID: 29475074 DOI: 10.1016/j.peptides.2018.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Leino TO, Turku A, Yli-kauhaluoma J, Kukkonen JP, Xhaard H, Wallén EA. Azulene-based compounds for targeting orexin receptors. European Journal of Medicinal Chemistry 2018;157:88-100. [DOI: 10.1016/j.ejmech.2018.07.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Equihua-Benítez AC, Guzmán-Vásquez K, Drucker-Colín R. Understanding sleep-wake mechanisms and drug discovery. Expert Opin Drug Discov 2017;12:643-57. [PMID: 28511597 DOI: 10.1080/17460441.2017.1329818] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
9 Turku A, Rinne MK, Boije Af Gennäs G, Xhaard H, Lindholm D, Kukkonen JP. Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity. PLoS One 2017;12:e0178526. [PMID: 28575023 DOI: 10.1371/journal.pone.0178526] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
10 Pagoria PF, Zhang M, Zuckerman NB, Dehope AJ, Parrish DA. Synthesis and characterization of multicyclic oxadiazoles and 1-hydroxytetrazoles as energetic materials. Chem Heterocycl Comp 2017;53:760-78. [DOI: 10.1007/s10593-017-2122-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
11 Turku A, Leino TO, Karhu L, Yli-Kauhaluoma J, Kukkonen JP, Wallén EAA, Xhaard H. Structure-Activity Relationships of 1-Benzoylazulenes at the OX1 and OX2 Orexin Receptors. ChemMedChem 2019;14:965-81. [PMID: 30892823 DOI: 10.1002/cmdc.201900074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Dale NC, Hoyer D, Jacobson LH, Pfleger KDG, Johnstone EKM. Orexin Signaling: A Complex, Multifaceted Process. Front Cell Neurosci 2022;16:812359. [DOI: 10.3389/fncel.2022.812359] [Reference Citation Analysis]
13 Karhu L, Magarkar A, Bunker A, Xhaard H. Determinants of Orexin Receptor Binding and Activation-A Molecular Dynamics Study. J Phys Chem B 2019;123:2609-22. [PMID: 30786708 DOI: 10.1021/acs.jpcb.8b10220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Rinne MK, Leino TO, Turku A, Turunen PM, Steynen Y, Xhaard H, Wallén EA, Kukkonen JP. Pharmacological characterization of the orexin/hypocretin receptor agonist Nag 26. European Journal of Pharmacology 2018;837:137-44. [DOI: 10.1016/j.ejphar.2018.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
15 Nepovimova E, Janockova J, Misik J, Kubik S, Stuchlik A, Vales K, Korabecny J, Mezeiova E, Dolezal R, Soukup O, Kobrlova T, Pham NL, Nguyen TD, Konecny J, Kuca K. Orexin supplementation in narcolepsy treatment: A review. Med Res Rev 2019;39:961-75. [PMID: 30426515 DOI: 10.1002/med.21550] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
16 Yang B, Li X, He L, Zhu Y. Computer-aided design of temozolomide derivatives based on alkylglycerone phosphate synthase structure with isothiocyanate and their pharmacokinetic/toxicity prediction and anti-tumor activity in vitro. Biomed Rep 2018;8:235-40. [PMID: 29599977 DOI: 10.3892/br.2018.1051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]